Limits...
Mitochondria selective S-nitrosation by mitochondria-targeted S-nitrosothiol protects against post-infarct heart failure in mouse hearts.

Methner C, Chouchani ET, Buonincontri G, Pell VR, Sawiak SJ, Murphy MP, Krieg T - Eur. J. Heart Fail. (2014)

Bottom Line: Infarct size and cardiac function were measured by magnetic resonance imaging (MRI) 24 h after infarction.MitoSNO-treated mice exhibited reduced infarct size and preserved function.MitoSNO action acutely at reperfusion reduces infarct size and protects from post-myocardial infarction heart failure.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

Show MeSH

Related in: MedlinePlus

Effects of mitochondria-targeted S-nitrosothiol (MitoSNO) on infarct size and heart function 24 h post-myocadial infarction (MI). (A) Representative heart cross-sections for infarct size assessment via histological 2,3,5-triphenyltetrazolium chloride (TTC) staining. (B) Quantification of TTC-stained infarcts. (C) Quantification of troponin I level in blood serum mirrored 24 h post-MI. (D) The infarct size quantification by late gadolinium-enhanced magnetic resonance imaging (LGE-MRI) 24 h post-MI for the MitoSNO-treated group compared with the untreated control group including representative images. (E) Assessment of LVEF 24 h post-MI. **P < 0.001; *P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4231226&req=5

fig02: Effects of mitochondria-targeted S-nitrosothiol (MitoSNO) on infarct size and heart function 24 h post-myocadial infarction (MI). (A) Representative heart cross-sections for infarct size assessment via histological 2,3,5-triphenyltetrazolium chloride (TTC) staining. (B) Quantification of TTC-stained infarcts. (C) Quantification of troponin I level in blood serum mirrored 24 h post-MI. (D) The infarct size quantification by late gadolinium-enhanced magnetic resonance imaging (LGE-MRI) 24 h post-MI for the MitoSNO-treated group compared with the untreated control group including representative images. (E) Assessment of LVEF 24 h post-MI. **P < 0.001; *P < 0.05.

Mentions: We first assessed whether this MitoSNO administration protocol protected against heart tissue damage measured by 2,3,5-triphenyltetrazolium chloride (TTC) staining 24 h post-reperfusion (Figure2A). This showed that a systemic i.v. bolus and infusion of MitoSNO beginning 5 min before reperfusion resulted in a significant reduction in infarct size (Figure2B) as well as significantly lower values of the clinically used marker, serum troponin I, 24 h post-MI in the MitoSNO-treated group (Figure2C).


Mitochondria selective S-nitrosation by mitochondria-targeted S-nitrosothiol protects against post-infarct heart failure in mouse hearts.

Methner C, Chouchani ET, Buonincontri G, Pell VR, Sawiak SJ, Murphy MP, Krieg T - Eur. J. Heart Fail. (2014)

Effects of mitochondria-targeted S-nitrosothiol (MitoSNO) on infarct size and heart function 24 h post-myocadial infarction (MI). (A) Representative heart cross-sections for infarct size assessment via histological 2,3,5-triphenyltetrazolium chloride (TTC) staining. (B) Quantification of TTC-stained infarcts. (C) Quantification of troponin I level in blood serum mirrored 24 h post-MI. (D) The infarct size quantification by late gadolinium-enhanced magnetic resonance imaging (LGE-MRI) 24 h post-MI for the MitoSNO-treated group compared with the untreated control group including representative images. (E) Assessment of LVEF 24 h post-MI. **P < 0.001; *P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4231226&req=5

fig02: Effects of mitochondria-targeted S-nitrosothiol (MitoSNO) on infarct size and heart function 24 h post-myocadial infarction (MI). (A) Representative heart cross-sections for infarct size assessment via histological 2,3,5-triphenyltetrazolium chloride (TTC) staining. (B) Quantification of TTC-stained infarcts. (C) Quantification of troponin I level in blood serum mirrored 24 h post-MI. (D) The infarct size quantification by late gadolinium-enhanced magnetic resonance imaging (LGE-MRI) 24 h post-MI for the MitoSNO-treated group compared with the untreated control group including representative images. (E) Assessment of LVEF 24 h post-MI. **P < 0.001; *P < 0.05.
Mentions: We first assessed whether this MitoSNO administration protocol protected against heart tissue damage measured by 2,3,5-triphenyltetrazolium chloride (TTC) staining 24 h post-reperfusion (Figure2A). This showed that a systemic i.v. bolus and infusion of MitoSNO beginning 5 min before reperfusion resulted in a significant reduction in infarct size (Figure2B) as well as significantly lower values of the clinically used marker, serum troponin I, 24 h post-MI in the MitoSNO-treated group (Figure2C).

Bottom Line: Infarct size and cardiac function were measured by magnetic resonance imaging (MRI) 24 h after infarction.MitoSNO-treated mice exhibited reduced infarct size and preserved function.MitoSNO action acutely at reperfusion reduces infarct size and protects from post-myocardial infarction heart failure.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

Show MeSH
Related in: MedlinePlus